Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 4/20 | 0.34 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.30 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19925432 | 0.84 | SCN1A (0.34) | SCN1ASCN8A | |
| SCHEMBL29464543 | 0.84 | SCN1A (0.34) | SCN1ASCN8A | |
| SCHEMBL29464538 | 0.76 | RORC (0.33) | SCN1ASCN8AHSD11B1 | |
| SCHEMBL19951366 | 0.76 | RORC (0.33) | SCN1ASCN8AHSD11B1 | |
| SCHEMBL19951401 | 0.76 | SCN9A (0.33) | SCN1ASCN8ABTK | |
| SCHEMBL19925421 | 0.76 | SCN9A (0.33) | SCN1ASCN8ABTK | |
| SCHEMBL19968877 | 0.75 | SCN1A (0.39) | SCN1ASCN8AHSD11B1 | |
| SCHEMBL19925180 | 0.73 | RORC (0.34) | SCN1ASCN8AHSD11B1 | |
| SCHEMBL19951451 | 0.73 | SCN9A (0.32) | SCN1ASCN8ABTK | |
| SCHEMBL19927721 | 0.73 | SCN9A (0.32) | SCN1ASCN8ABTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2021-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | SCN1A 32/4885SCN8A 450/4885HSD11B1 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.